COVID-19 updates based on what experts on Twitter are talking about.
Support on BuyMeACoffee to help this project continue!
Sign up for email updates · Twitter: @covidpath
· Facebook group
Percentage vaccinated with at least one dose
| AK
46.0% | AL
36.0% | AR
39.4% | AZ
46.0% | CA
56.4% |
| CO
53.9% | CT
63.0% | DE
54.4% | FL
48.8% | GA
39.0% |
| HI
66.4% | IA
49.0% | ID
37.5% | IL
54.6% | IN
41.6% |
| KS
46.7% | KY
46.2% | LA
35.6% | MA
66.0% | MD
57.2% |
| ME
63.1% | MI
48.6% | MN
54.2% | MO
42.0% | MS
34.0% |
| MT
45.1% | NC
43.3% | ND
42.1% | NE
48.2% | NH
59.7% |
| NJ
59.9% | NM
57.5% | NV
45.3% | NY
55.4% | OH
45.6% |
| OK
41.4% | OR
54.5% | PA
58.1% | RI
60.6% | SC
40.7% |
| SD
48.1% | TN
39.0% | TX
44.0% | UT
44.9% | VA
55.0% |
| VT
70.0% | WA
56.3% | WI
50.9% | WV
40.5% | WY
37.0% |
| DC
56.8% |
| A.Samoa
42.1% | M'nesia
24.1% | Guam
53.7% | Marsh.I
27.7% | N.Mar'na
45.7% |
| P'rto R.
50.4% | Palau
73.5% | V'gin Is
36.1% |
Percentage 65+ vaccinated with at least one dose
| AK
79.9% | AL
76.0% | AR
75.9% | AZ
82.2% | CA
90.6% |
| CO
85.8% | CT
93.3% | DE
91.4% | FL
87.7% | GA
78.8% |
| HI
98.3% | IA
87.4% | ID
79.0% | IL
87.9% | IN
80.9% |
| KS
90.4% | KY
83.8% | LA
76.7% | MA
94.6% | MD
88.5% |
| ME
93.4% | MI
82.9% | MN
90.1% | MO
78.6% | MS
74.8% |
| MT
80.6% | NC
78.9% | ND
82.5% | NE
86.3% | NH
91.6% |
| NJ
90.0% | NM
90.2% | NV
79.8% | NY
83.2% | OH
82.1% |
| OK
81.6% | OR
84.2% | PA
98.2% | RI
93.8% | SC
82.3% |
| SD
90.3% | TN
76.7% | TX
81.3% | UT
86.1% | VA
87.1% |
| VT
99.9% | WA
88.7% | WI
88.8% | WV
73.9% | WY
75.4% |
| DC
82.4% |
| A.Samoa
26.9% | M'nesia
12.1% | Guam
51.3% | Marsh.I
9.8% | N.Mar'na
26.9% |
| P'rto R.
81.0% | Palau
53.4% | V'gin Is
68.2% |
Source: CDC
Here’s the key table from @PHE_uk new report on vaccine efficacy against hospitalisation with Delta variant:
— John Burn-Murdoch (@jburnmurdoch) June 14, 2021
After 1 dose
• Pfizer: 94% effective
• AstraZeneca: 71% effective
After 2 doses
• Pfizer: 96%
• AstraZeneca: 92%
Full preprint here: https://t.co/JQQjo0gSdg pic.twitter.com/osSjIZ0eA6
Novavax's long-awaited results of its US-Mexico Phase 3 trial shows that its #Covid19 vaccine performs about as well as the mRNA vaccines, protecting about 90% of recipients. This vaccine should play a big role internationally. https://t.co/jw5PxRnVO3
— Helen Branswell (@HelenBranswell) June 14, 2021
Scientists are looking into whether the "one-and-done" vaccines could benefit from a Pfizer or Moderna booster.
— Amy Maxmen, PhD (@amymaxmen) June 14, 2021
This seems like important research to follow in the coming months. By @rkhamsi https://t.co/odRziA8MiK
Novavax’s big US-Mexico trial confirmed their protein vaccine works well, with 90 percent efficacy. It’s late for the US, but not for the world. And it might prove a good booster too. Here is my story for @nytimes https://t.co/YGvfB5QZd7
— Carl Zimmer (@carlzimmer) June 14, 2021
Though it is newly respectable, the Wuhan lab theory remains fanciful | David Robert Grimes https://t.co/RlEcuPXnEK
— ɪᴀɴ ᴍ. ᴍᴀᴄᴋᴀʏ, ᴘʜᴅ 🦠🤧🧬🥼🦟🧻🧙♂️ (@MackayIM) June 13, 2021
-persistent infection barely mentioned
— ɪᴀɴ ᴍ. ᴍᴀᴄᴋᴀʏ, ᴘʜᴅ 🦠🤧🧬🥼🦟🧻🧙♂️ (@MackayIM) June 13, 2021
The four most urgent questions about long COVID https://t.co/S01vUco5hE
The #G7 this weekend renounced its role as #globalhealth leader, @kentbuse and I argue in @bmj_latest: https://t.co/E0G6mOzNH2
— Katri Bertram (@KatriBertram) June 14, 2021
A thread on what next for global health & #healthsecurity.
Houston Methodist was the 1st hospital system in U.S. to require all employees to get vaccinated. “U.S. District Judge Lynn N. Hughes said federal law does not prevent employers from issuing that mandate.” https://t.co/D1DYKpjQQ9
— Connie Schultz (@ConnieSchultz) June 13, 2021
so it turns out that Amoy Gardens outbreak wasn't *quite* as localized as a lot of people believe, & spread to neighbouring complexes: https://t.co/4FryktwyTH
— Jasnah Kholin - 8964 - ACAB - 💉💉 (@wanderer_jasnah) June 13, 2021
Atrocities in #Tigray must stop and an immediate humanitarian ceasefire be put in place. Ending the crisis in Tigray is a priority for the UK and @G7 partners, and a credible political process is needed. 👇https://t.co/UCX9v9RxSo
— James Duddridge MP (@JamesDuddridge) June 13, 2021
To turn this promise into reality, we urge the G7 to:
— Henrietta H. Fore (@unicefchief) June 13, 2021
🚨 Start to #DonateDosesNow to close the gap this summer.
🚨 Ensure there’s enough money to get vaccines off the tarmac and into arms. https://t.co/9n4WRLczje
Covid (@UCSF) Chronicles, Day 453
— Bob Wachter (@Bob_Wachter) June 13, 2021
1/ I know everybody’s sick of playing 3-dimensional Covid chess. Sorry, but the Delta variant forces us back to the chess board. Ergo, this 🧵.
If you’re fully vaxxed, I wouldn’t be too worried, especially if you’re in a highly vaxxed region.
I'm very concerned about the delta variant. It's still not clear to me that it's more pathogenic, but it is more transmissible, including among people who are partially vaccinated.
— Dr. Angela Rasmussen (@angie_rasmussen) June 14, 2021
This got me thinking about the J&J vaccine, and how maybe it's time to think about mRNA boosters.
The return of vaccine Monday, but maybe one of the last placebo-controlled trial results. In their large US/Mexico trial, Novavax confirms the excellent result seen in an earlier UK trial. This includes efficacy against the circulating alpha (UK) variant. https://t.co/CdOmqM7dFi
— Natalie E. Dean, PhD (@nataliexdean) June 14, 2021
Media briefing on #COVID19 with @DrTedros https://t.co/3Qt3o0ZJJZ
— World Health Organization (WHO) (@WHO) June 14, 2021
Happy #WorldBloodDonorDay!
— World Health Organization (WHO) (@WHO) June 14, 2021
Despite the #COVID19 pandemic, young people around the world continue to play a key role in ensuring a safe blood supply.
👏A big thanks for their incredible contribution to the health of their communities 👉https://t.co/tYTUnMX3xU pic.twitter.com/yJmqOpXhp0
Good news for global vaccine equity. The Novavax COVID-19 vaccine had 90% efficacy against any symptomatic disease and ~100% efficacy against severe disease & death.
— Saad B. Omer (@SaadOmer3) June 14, 2021
COVAX has reserved 1.1 billion doses of this vaccine + enables further US donations https://t.co/v62FneMGPL
New report on mRNA vaccine effectiveness vs the #DeltaVariant @PHE_uk supports pivotal importance of 2nd dose and consistent with the Qatar @NEJM report with the beta variant https://t.co/H5VThMnosrhttps://t.co/0RJo7Fg3hP pic.twitter.com/j0zg83CaqQ
— Eric Topol (@EricTopol) June 14, 2021
Short 🧵
— Maria Van Kerkhove (@mvankerkhove) June 14, 2021
There is a lot of concern over the Delta (B.1.617.2) variant and there should be. The #SARSCoV2 virus is dangerous, & more transmissible variants are even more dangerous.
(Keep reading…)@WHO #COVID19 https://t.co/YKkT6TXPif
New data and good news
— Ashish K. Jha, MD, MPH (@ashishkjha) June 14, 2021
Novovax phase 3 trial results of its COVID vaccine
90% overall efficacy
100% against severe disease
91% in high risk folks
And seems to work against variants
All we have is press release
But if it holds up, it'll be importanthttps://t.co/XRTSJGuAqA
The delta variant is not an "escape" variant. Full mRNA vaccine regimens provide excellent protection against delta. But viruses that can infect partially vaccinated people will evolve under immune selection pressure. We should aim to prevent infections altogether.
— Dr. Angela Rasmussen (@angie_rasmussen) June 14, 2021
NEWS -- Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
— Public Health England (@PHE_uk) June 14, 2021
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
In an era where good news is in short supply, this analysis from Public Health England suggests that both Pfizer & AstraZeneca are highly effective against hospitalization with the Delta variant (after 2 doses):
— Isaac Bogoch (@BogochIsaac) June 14, 2021
1. Pfizer: 96%
2. AstraZeneca: 92%
Link: https://t.co/Z5WhspIdtQ
NEW: Meet Vin Gupta, the veteran-turned-lung-doc shepherding Amazon's health efforts onto the public stage while balancing news spots, weekend ICU shifts, health research & of course, tweeting. (It is unclear when he sleeps.) https://t.co/hwEGIWyH3g
— Erin Brodwin ⚡ (@erbrod) June 14, 2021
Very good. https://t.co/SoURVeTw4O
— Florian Krammer (@florian_krammer) June 14, 2021
I would very much appreciate help from everyone in forwarding my newsletter (https://t.co/wF29VL5kz2) and the preprint (linked in the newsletter) to any medical statisticians you might know. This argument is important.
— Anders Huitfeldt (@AndersHuitfeldt) June 14, 2021
It would also be great if PH leaders could acknowledge the very important and substantial gap in efficacy between AZ and mRNA vaccines. That gap really matters now.
— David Fisman (@DFisman) June 14, 2021
It’s always baffled me that the expectation is you only call in sick if you are “really” sick. Especially in virology labs where this ethic directly contradicts to good biosafety practices.
— Dr. Angela Rasmussen (@angie_rasmussen) June 14, 2021
Normalize staying home even if you aren’t too sick to work. https://t.co/sIopH8fzW1
Pro-tips for reading this tweet.
— Eli Perencevich, MD MS🧼 😷 (@eliowa) June 14, 2021
1) morbidity≠mortality. Confusing them proves my point
2) “a top cause” ≠ “the top cause”
3) read it again. I never used the word vaccine. Your bias is showing 😊 https://t.co/BLzfeUEA28
Tl;dr 😦 pic.twitter.com/9Gvmkef9oY
— Wellcome (@wellcometrust) June 14, 2021
"The global decline masks a worrying increase in cases and deaths in many countries. The steep increase in Africa is especially concerning, because it is the region with the least access to vaccines, diagnostics and oxygen"-@DrTedros #COVID19
— World Health Organization (WHO) (@WHO) June 14, 2021